Immuron Limited · ASX:IMC
Immuron — Shareholder Meeting (November 2015)
12 slides from Immuron's shareholder meeting presentation, Nov 25, 2015
Slide 1: 2015 AGM Presentation
For personal use only 2015 AGM PRESENTATION November 2015
Slide 2: Forward-Looking Statement
Forward-Looking Statement For personal use only Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guida
Slide 3: Investment Highlights
Immuron Limited Investment Highlights For personal use only Travelan sales growing in multiple Growing OTC countries and positioned to grow further Business with successful USA launch; No competition Phase II in Fatty-Liver Disease (NASH) – No approved therapy; $35-$40B market by Strong Pipeline wit
Slide 4: Pipeline: Strong Asset Portfolio Mix
Pipeline Strong Asset Portfolio Mix For personal use only Pre-Clinical Phase 1 Phase 2 Phase 3 On Market Launched in multiple geographies IMM-124E Fatty-Liver Disease (NASH) Alcoholic Fatty-Liver Disease IMM-124E (ASH) (Funded by the NIH) C- IMM-524 Difficile 4
Slide 5: FY2015 Year in Review
FY2015 Year in Review For personal use only • US: Launch and first major North American Travelan Distribution Agreement signed OTC • Canada: Launch by Paladin (Endo) • China: Distribution and registration Agreement signed • Protectyn: Brand, packaging development • NASH: Start of Phase II Rx • ASH:
Slide 6: FY2015 Share Performance
FY2015 Share Performance For personal use only Share Price Performance (July 1, 2014 – Nov 24, 2015) NASH Recruitment Update RedChip Research Report Released Travelan US Launch Travelan China Agreement Signed 6
Slide 7: FY2016 Major Goals and Objectives
FY2016 Major Goals and Objectives For personal use only • US: Accelerate market penetration • China: CFDA approval; Push products through more OTC creative channels (Travelan/Protectyn) • Protectyn: Launch in AUS; Launch in other territories • Expand Geographic partners: Korea, EU, Japan, etc. • NAS
Slide 8: FY2016 June – November Accomplishments
FY2016 June – November Accomplishments For personal use only • US: Redesigned label and messaging • US: 3 more distribution partners signed • WW: Multiple partnership discussions ongoing • Launch of Protectyn in AUS • Planning for launch in other markets • Israel sites added to the study • Recruitme
Slide 9: Travelan: A Growing Global Brand
Travelan® A Growing Global Brand For personal use only Today Future Regional Brand: Global Brand: –Launched: US, CA, US –Expand to: Europe, Russia, Rest Markets –In registration: China of Asia, and South Korea –Own marketing and/or Licensing Consumer Focused: All Relevant Channels: –Travel Clinics –
Slide 10: NASDAQ Listing: Progress and Rationale
NASDAQ LISTING Progress and Rationale For personal use only • US underwriter and SEC counsel partners vetted and hired Progress • Process already underway • Targeting February / March listing • Access to US capital markets and investors is critical to long-term growth of the company Rationale • Incr
Slide 11: FY2016 Summary: Focus on Three Key Valuation Levers
FY2016 Summary Focus on Three Key Valuation Levers For personal use only Expand and Maximize OTC Business Execute Prioritized Rx Program NASDAQ Listing and Careful Capital Allocation 11
Slide 12: Thank You
For personal use only THANK YOU